58,747
Participants
Start Date
September 1, 2020
Primary Completion Date
September 30, 2022
Study Completion Date
September 30, 2022
Azithromycin
The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
Placebo
Identical appearing placebo, administered as a single oral dose directly after randomization.
ICDDRB, Dhaka
Moi University School of Medicine, Eldoret
The Aga Khan University, Karachi
Kinshasa School of Public Health, Kinshasa
Lata Medical Research Foundation, Nagpur
University Teaching Hospital, Lusaka
Institute for Nutrition of Central America and Panama (INCAP), Guatemala City
Jawaharlal Nehru Medical College, Belagām
University of Alabama at Birmingham
OTHER
University Teaching Hospital, Lusaka, Zambia
OTHER
University of North Carolina, Chapel Hill
OTHER
Kinshasa School of Public Health
OTHER
University of Colorado, Denver
OTHER
Institute of Nutrition of Central America and Panama
OTHER
University of Virginia
OTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Thomas Jefferson University
OTHER
Columbia University
OTHER
Aga Khan University
OTHER
Boston University
OTHER
Lata Medical Research Foundation, Nagpur
OTHER
Indiana University School of Medicine
OTHER
Moi Univeristy
OTHER
RTI International
OTHER
Bill and Melinda Gates Foundation
OTHER
Jawaharlal Nehru Medical College
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
NICHD Global Network for Women's and Children's Health
NETWORK